4D MOLECULAR THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.53 USD | -2.97% |
|
-5.04% | +16.14% |
Presenter SpeechUnknown Analyst (Analysts)Okay, everybody. Good morning. Welcome to our contin...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
23.53
USD
Average target price
54.22
USD
Spread / Average Target
+130.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.14% | 1.2B | |
| +1.12% | 42.59B | |
| +6.77% | 40.65B | |
| +47.58% | 40.57B | |
| -11.96% | 26.77B | |
| +6.01% | 24.81B | |
| -24.92% | 18.17B | |
| -3.63% | 11.7B | |
| +27.16% | 12.05B | |
| +7.30% | 11.1B |
- Stock Market
- Equities
- FDMT Stock
- News 4D Molecular Therapeutics, Inc.
- Transcript : 4D Molecular Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 08
